Package Leaflet: Information for the User
Ezetimiba/Simvastatina Kern Pharma 10 mg/40 mg Film-coated Tablets
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of thePackage Leaflet
This medicationcontains the active principles ezetimiba and simvastatina.It is used to reduce total cholesterol, "bad" cholesterol (LDL cholesterol) and certain fatty substances called triglycerides that circulate in the blood. Additionally, it increases the concentrations of "good" cholesterol (HDL cholesterol).
Ezetimiba/simvastatinaacts by reducing cholesterol in two ways. The active principle ezetimiba reduces the cholesterol absorbed in the digestive tract. The active principle simvastatina, which belongs to the group of "statins", inhibits the production of cholesterol produced by the body itself.
Cholesterol is one of the fatty substances found in the bloodstream. Its total cholesterol is composed mainly of LDL and HDL cholesterol.
LDL cholesterol is often referred to as "bad" cholesterol because it can accumulate in the walls of its arteries, forming plaques. Over time, this accumulation of plaque can cause a narrowing of the arteries. This narrowing can make blood flow to vital organs such as the heart and brain slower or interrupted. This interruption of blood flow can cause a heart attack or stroke.
HDL cholesterol is often referred to as "good" cholesterol because it helps to prevent bad cholesterol from accumulating in the arteries and protects them from cardiovascular diseases.
Triglycerides are another type of fat in your blood that can increase the risk of heart disease.
Ezetimiba/simvastatinais used in patients who cannot control their cholesterol levels solely with diet. While taking this medication, you must follow a cholesterol-reducing diet.
Ezetimiba/simvastatinais used, along with a cholesterol-reducing diet,if you have:
This medicationdoes not help you lose weight.
Do not take Ezetimiba/SimvastatinaKern Pharmaif:
Do not take more than 10/40 mg of ezetimiba/simvastatina if you are taking lomitapida (used to treat rare and severe genetic cholesterol disorders).
Consult your doctor if you are unsure if your medication is mentioned above.
Warnings and precautions
Inform your doctor:
Your doctor will perform a blood test before you start taking ezetimiba/simvastatina and also if you have any symptoms of liver problems while taking ezetimiba/simvastatina. This is to check how well your liver is working.
Your doctor may also want to perform blood tests to check how well your liver is working after you start taking ezetimiba/simvastatina.
While you are taking this medication, your doctor will monitor if you have diabetes or are at risk of developing diabetes. This risk of diabetes increases if you have high levels of sugar and fats in your blood, overweight and high blood pressure.
Talk to your doctor if you have a severe lung disease.
You should avoid taking ezetimiba/simvastatina and fibrates (certain medications to reduce cholesterol) together, as the combination has not been studied.
Consult your doctor immediately if you experience unexplained muscle pain, sensitivity to pressure or muscle weakness. This is because, in rare cases, muscle problems can be severe, including renal failure; and very rarely, deaths have occurred.
The risk of muscle failure is higher with high doses of ezetimiba/simvastatina, especially the 10/80 mg dose. The risk of muscle failure is also higher in certain patients. Inform your doctor in the following situations:
Also inform your doctor or pharmacist if you experience persistent muscle weakness. Additional tests and medications may be necessary to diagnose and treat this problem.
Children and adolescents
Other medications and Ezetimiba/SimvastatinaKern Pharma
Inform your doctor if you are taking, have taken recently or may need to take any other medication with any of the following active ingredients. Taking ezetimiba/simvastatina with any of the following medications may increase the risk of muscle problems (some of these are already included in the section above "Do not take Ezetimiba/SimvastatinaKern Pharmaif").
As with the medications mentioned above, inform your doctor or pharmacist if you are taking or have taken recently other medications, even those purchased without a prescription. In particular, inform your doctor if you are taking any of the following:
You should also inform any doctor who prescribes a new medication that you are taking ezetimiba/simvastatina.
Taking Ezetimiba/SimvastatinaKern Pharmawith food and drinks
Orange juice contains one or more components that alter the metabolism of some medications, including ezetimiba/simvastatina. You should avoid consuming orange juice, as it may increase the risk of muscle problems.
Pregnancy and breastfeeding
Do not take this medication if you are pregnant, trying to become pregnant or think you may be pregnant. If you become pregnant while taking ezetimiba/simvastatina, stop taking it immediately and inform your doctor. Do not take ezetimiba/simvastatina if you are breastfeeding, as it is unknown whether this medication passes into breast milk.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
Ezetimiba/simvastatina is not expected to interfere with your ability to drive or operate machinery. However, some people may experience dizziness after taking ezetimiba/simvastatina.
This medication contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Your doctor will determine the appropriate dose for you, based on your current treatment and personal risk situation.
The tablets do not have a notch and should not be divided.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Adults: the dose is1 tabletof ezetimiba/simvastatina once a day by oral route.
Use in adolescents(10 to 17 years old): the dose is1 tabletof ezetimiba/simvastatina once a day by oral route (do not exceed a maximum dose of 10mg/40mg once a day).
The ezetimiba/simvastatina 10mg/80mg dose is only recommended for adult patients with very high cholesterol levels and a high risk of heart disease problems who have not achieved treatment goals with lower doses.
Take ezetimiba/simvastatina at night. You can take it with or without food.
If your doctor has prescribed ezetimiba/simvastatina together with another cholesterol-lowering medication that contains the active ingredient colestiramine or any other bile acid sequestrant, you should take ezetimiba/simvastatina at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If you take more Ezetimiba/Simvastatina Kern Pharmathan you should
If you forgot to take Ezetimiba/Simvastatina Kern Pharma
If you interrupt the treatment with Ezetimiba/Simvastatina Kern Pharma
If you have any other questions about the use of this product, ask your doctor or pharmacist.
The following frequent side effects (may affect up to 1 in 10 people) have been reported:
The following infrequent side effects (may affect up to 1 in 100 people) have been reported:
Adverse reactions of unknown frequency (cannot be estimated from available data):
Consult your doctor if you experience weakness in your arms or legs that worsens after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or difficulty breathing.
In addition, the following side effects have been reported in people taking ezetimiba/simvastatina or medications containing the active ingredients ezetimiba or simvastatina:
The following very rare severe side effects have been reported: a severe allergic reaction that causes difficulty breathing or dizziness (anaphylactic reaction).
With some statins, the following additional adverse events have been reported:
If any of these severe side effects occur, stop taking the medication and immediately inform your doctor or go to the nearest hospital emergency room.
Consult your doctor immediately if you experience unexplained muscle pain, sensitivity to pressure, or weakness. This is because, in rare cases, muscle problems can be severe, including muscle failure, which can cause kidney damage; and very rarely, deaths have occurred.
Reporting of side effects:
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:
https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Medicines should not be disposed of through drains or in the trash. Dispose of packaging and unused medicines at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and unused medicines. By doing so, you will help protect the environment.
Composition of Ezetimiba/Simvastatina Kern Pharma
The active principles are ezetimiba and simvastatina. Each tablet contains 10 mg of ezetimiba and 40 mg of simvastatina.
The other components are: lactose monohydrate, hypromellose, sodium croscarmellose,
microcrystalline cellulose, ascorbic acid, anhydrous citric acid, butylated hydroxyanisole, propyl gallate, magnesium stearate, yellow iron oxide, red iron oxide, black iron oxide.
Appearance of the product and content of the packaging
The Ezetimiba/Simvastatina Kern Pharma 10/40 mg tabletsare round, biconvex, white to bone-colored tablets, speckled and engraved with “513” on one face.
Packaging sizes:
28 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Kern Pharma, S.L.
Venus, 72 - Pol. Ind.Colón II
08228 Terrassa - Barcelona
Spain
Responsible for manufacturing
Balkanpharma-Dupnitsa AD,
3 Samokovsko Shosse Street,
Dupnitsa, 2600,
Bulgaria
or
Actavis Ltd.
BLB015-016, Bulebel Industrial Estate
Zejtun ZTN 3000
Malta
Last review date of this leaflet: May 2023
The detailed and updated information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.es
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.